Opko Health (NASDAQ: OPK) and BioDelivery Sciences International (NASDAQ:BDSI) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk and profitability.
This table compares Opko Health and BioDelivery Sciences International’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BioDelivery Sciences International||10.40%||33.83%||6.43%|
22.9% of Opko Health shares are owned by institutional investors. Comparatively, 44.2% of BioDelivery Sciences International shares are owned by institutional investors. 40.2% of Opko Health shares are owned by insiders. Comparatively, 7.7% of BioDelivery Sciences International shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Opko Health and BioDelivery Sciences International’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Opko Health||$1.22 billion||2.28||-$25.08 million||($0.19)||-26.26|
|BioDelivery Sciences International||$15.55 million||9.77||-$67.13 million||($0.19)||-14.32|
Opko Health has higher revenue and earnings than BioDelivery Sciences International. Opko Health is trading at a lower price-to-earnings ratio than BioDelivery Sciences International, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Opko Health has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500. Comparatively, BioDelivery Sciences International has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.
This is a breakdown of recent ratings and target prices for Opko Health and BioDelivery Sciences International, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BioDelivery Sciences International||0||1||5||0||2.83|
Opko Health presently has a consensus target price of $14.81, suggesting a potential upside of 196.84%. BioDelivery Sciences International has a consensus target price of $4.50, suggesting a potential upside of 65.44%. Given Opko Health’s higher probable upside, research analysts plainly believe Opko Health is more favorable than BioDelivery Sciences International.
Opko Health beats BioDelivery Sciences International on 7 of the 13 factors compared between the two stocks.
Opko Health Company Profile
OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women’s Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.